Major Updates in Nephrology: Evidence-Based Practice Changes

SGLT2 Inhibitors: The New Standard of Care

SGLT2 inhibitors are now recommended for nearly all CKD patients, representing the most transformative change in nephrology practice. The 2024 KDIGO guidelines establish SGLT2i as foundational therapy with unprecedented strength of evidence 1.

Who Gets SGLT2 Inhibitors:

Type 2 diabetes + CKD with eGFR ≥20: Strong recommendation (1A) 1
Non-diabetic CKD with ACR ≥200 mg/g and eGFR ≥20: Strong recommendation (1A) 1
Heart failure with CKD: Strong recommendation regardless of albuminuria (1A) 1
eGFR 20-45 with ACR <200 mg/g: Conditional recommendation (2B) 1

Critical Practice Changes:

Continue SGLT2i even when eGFR drops below 20 unless intolerance or dialysis initiation 1
The initial eGFR dip is not an indication to stop—this is a reversible hemodynamic effect 1
Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
No need to increase monitoring frequency after initiation 1

This represents a paradigm shift: SGLT2i are no longer just diabetes drugs but kidney-protective agents for most CKD patients.

Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs)

Finerenone and similar nonsteroidal MRAs now have a defined role as add-on therapy for high-risk diabetic CKD patients. 1, 2

When to Use:

Type 2 diabetes with eGFR >25 ml/min/1.73 m²
Normal potassium at baseline
Persistent albuminuria (>30 mg/g) despite maximum tolerated RASi
Conditional recommendation (2A) 1

Key Implementation Points:

Can be combined with RASi AND SGLT2i for triple therapy 1
Select patients with consistently normal potassium and monitor closely 1
Prioritize agents with documented kidney/cardiovascular benefits (finerenone) 1
Most appropriate for high-risk patients with persistent albuminuria despite standard therapy 1

The finerenone-empagliflozin combination has shown significant nephroprotective benefits 3.

RAS Inhibitor Management: Continue Longer Than You Think

Continue ACEi/ARB even when eGFR falls below 30 ml/min/1.73 m²—a practice point that contradicts older conservative approaches 1.

Updated Stopping Criteria:

Don't stop for eGFR decline alone, even below 30
Do stop if:
- Creatinine rises >30% within 4 weeks of initiation/dose increase 1
- Symptomatic hypotension 1
- Uncontrolled hyperkalemia despite medical management 1
- To reduce uremic symptoms in advanced kidney failure (eGFR <15) 1

Hyperkalemia Management:

Manage hyperkalemia with potassium-lowering strategies rather than stopping RASi 1. This is a critical shift—the benefits of continued RASi often outweigh the inconvenience of hyperkalemia management.

Anemia Management: New Agents and Updated Thresholds

The 2026 KDIGO anemia guideline introduces significant changes 4, 5.

Iron Therapy Updates:

More proactive intravenous iron thresholds, especially for hemodialysis patients 4. The guideline emphasizes comprehensive evaluation at diagnosis to identify causes beyond erythropoietin deficiency 4.

ESAs vs. HIF-PHI:

Erythropoiesis-stimulating agents (ESAs) remain the preferred first-line therapy over hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) due to:

Persistent cardiovascular safety concerns with HIF-PHIs 4
Methodological limitations in available HIF-PHI trials 4
Regional regulatory differences (European vs. US approvals) 4

However, HIF-PHIs (like roxadustat, daprodustat) are now available and guideline-addressed for specific situations 6, 5.

Special Considerations:

Iron deficiency without anemia in CKD now has specific guidance 6
Treatment should be individualized based on comprehensive patient evaluation 4
Consider interactions with SGLT2 inhibitors 4

GLP-1 Receptor Agonists: Kidney Protection Beyond Diabetes

Long-acting GLP-1 RAs are recommended for T2D + CKD patients not at glycemic targets despite metformin and SGLT2i (1B recommendation) 1.

Key Points:

Prioritize agents with documented cardiovascular benefits 1
Kidney-protective effects now recognized beyond glycemic control 2
Oral semaglutide showing efficacy in cardiovascular risk reduction and being evaluated for CKD progression prevention 3

Acute Kidney Injury and Dialysis Initiation

New S3 guidelines (2025) provide structured RRT recommendations 7.

Absolute Indications for Immediate RRT:

Life-threatening refractory hypervolemia
Severe electrolyte disturbances
Severe acid-base disturbances
Uremic complications 7

Early vs. Conservative Strategy:

Without absolute indications, start RRT proactively if the clinical picture (comorbidities, trajectory, current condition) suggests high likelihood of RRT necessity 7. Otherwise, conservative management is appropriate.

Technical Considerations:

Continuous and intermittent techniques are therapeutically equivalent 7
Prioritize continuous/prolonged procedures for hemodynamic instability 7
Use diffusive procedures with high dialysis flow for severe hyperkalemia 7
Regional citrate anticoagulation preferred for bleeding risk 7
Continuous RRT: effluent dose 20-25 ml/kg/h 7

Weaning:

Correct volume overload, hyperkalemia, and metabolic acidosis before attempting 7
Return of spontaneous diuresis is the most reliable predictor 7
Stable renal function for ≥7 days defines primary weaning success 7
All AKI survivors need structured outpatient follow-up 7

Emerging Therapies on the Horizon

Novel Agents in Development:

Atrasentan (endothelin type A receptor antagonist): Demonstrated efficacy in IgA nephropathy 3
Iptacopan (oral factor B inhibitor): Effective in IgA nephropathy and C3 glomerulopathy 3
Obinutuzumab (anti-CD20 antibody): Showing efficacy in lupus nephritis 3
Baxdrostat (aldosterone synthase inhibitor): Efficacy in resistant hypertension, being evaluated for CKD progression 3

Diagnostic Advances:

CKDx framework (chronic kidney disease of unexplained cause): New standardized approach integrating genetic and histological testing 3.

Blood Pressure Targets

Adults:

Target SBP <120 mmHg for most CKD patients (based on SPRINT-like protocols)
Balance against orthostatic hypotension risk 1

Pediatrics:

24-hour MAP by ABPM ≤50th percentile for age, sex, height (2C) 1
Monitor with ABPM annually and standardized office BP every 3-6 months 1
When ABPM unavailable: target office SBP 50th-75th percentile 1

Metabolic Acidosis and Hyperkalemia

Acidosis:

Consider pharmacological treatment ± dietary intervention to prevent serum bicarbonate <18 mmol/L 1
Monitor to avoid exceeding upper limit of normal and adverse effects on BP, potassium, or fluid status 1

Hyperkalemia:

Be aware of measurement variability (diurnal, seasonal, plasma vs. serum) 1
Newer potassium binders available but subject to local formulary restrictions 1

Critical Implementation Pitfalls

Don't stop SGLT2i for initial eGFR dip—this is expected and not harmful 1
Don't discontinue RASi prematurely for mild hyperkalemia—manage the potassium instead 1
Don't avoid RASi when eGFR drops below 30—continue unless specific contraindications 1
Don't rush to HIF-PHIs as first-line anemia therapy—ESAs remain preferred 4
Don't forget structured post-AKI follow-up—all survivors need outpatient monitoring 7

Future Directions

By 2050, nephrology is projected to transform from reactive kidney failure management to proactive kidney health preservation through:

AI-enabled risk prediction and digital twins
Multi-omics profiling for precision medicine
Xenotransplantation and bioengineered kidneys
Regenerative medicine approaches 8

However, current challenges include unequal access to innovative treatments, gaps in early screening, and climate change impacts on kidney function 3.

What are the recent evidence‑based updates in nephrology for managing chronic kidney disease, anemia, hyperkalemia, acute kidney injury, dialysis initiation, home dialysis, and kidney transplantation?

Have a follow-up question?